Welcome to the new world of interventional diabetes. Based on new data, institutions offering gastric bypass surgeries for weight loss are now recasting them as treatments for type 2 diabetes. This is a dramatic change in perspective within the drug-oriented diabetology world. Now MetaCure hopes to take that interventional notion a step further, with a minimally-invasive and reversible therapy based on electrical stimulation applied to the stomach.
Based on new data, institutions offering gastric bypass surgeries, Allergan Inc.’s minimally invasive LapBands, and other surgeries for weight loss are now recasting them as treatments for Type 2 diabetes. This is a dramatic change in perspective within the drug-oriented diabetology world.
Studies of the surgical treatment of obesity and its beneficial effect on patients with Type 2 diabetes go back to...
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
